Key Performance
More- Earnings Score: 38
- Momentum Score: 81
- True Yield: N/A
- Financial Health Score: 25
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.
08/31/2026, 10:53 AM • GlobeNewswire
The global animal testing and non-animal alternative testing market reached $15.19 billion in 2025 and is projected to grow to $23.01 billion by 2035 at a CAGR of 4-4.5%. While animal testing dominated with 80.1% market share in 2025, non-animal alternative testing is expected to grow faster at 6.3% CAGR through 2030, driven by advances in organ-on-chip, organoids, AI biosimulation, and genomics. The pharmaceutical industry led end-user applications with 50.1% market share, while North America was the largest regional market at 38.6% of global revenue.
08/27/2026, 6:52 AM • GlobeNewswire
The global large molecule bioanalytical testing services market is projected to grow from USD 3.11 billion in 2026 to USD 5.88 billion by 2035, with a CAGR of 7.3%. Growth is driven by increasing biologics pipelines, demand for personalized therapies, and outsourcing to CROs and CDMOs. Pharmacokinetics testing dominates at 45% of market revenue, while bioequivalence testing is expected to grow fastest. North America leads with 50% of global revenue, while Asia-Pacific is the fastest-growing region at 8.6% CAGR.
08/26/2026, 7:58 AM • GlobeNewswire
The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.
07/15/2026, 6:46 AM • GlobeNewswire
The cell and gene therapy CDMO market is projected to grow from USD 8.3 billion in 2025 to USD 57.1 billion by 2034, driven by increasing clinical development of advanced therapies, rising outsourcing trends among biopharma companies, and technological advancements in manufacturing. North America leads the market with 40% share, while Asia-Pacific emerges as a significant growth hub. Key players are expanding manufacturing capabilities through strategic partnerships.
06/18/2026, 1:00 PM • GlobeNewswire
The cell banking outsourcing market is projected to grow from USD 16.78 billion in 2025 to USD 42.31 billion by 2031, with a CAGR of 16.71%. Growth is driven by increasing demand for biologics, cell and gene therapies, and regenerative medicine. North America leads the market while Asia-Pacific emerges as a high-growth region. Biopharmaceutical companies are increasingly outsourcing cell banking operations to improve efficiency and reduce costs.
05/25/2026, 4:15 AM • GlobeNewswire
The plasmid DNA manufacturing market is projected to grow from USD 2.4 billion in 2025 to USD 10.8 billion by 2034, driven by rising demand for gene therapies, DNA vaccines, and CAR-T treatments. North America leads the market with 44.12% share, while Asia-Pacific emerges as a significant growth engine. Major companies are expanding GMP-compliant manufacturing capabilities to meet increasing demand from biopharmaceutical companies and CDMOs.
05/04/2026, 1:00 PM • GlobeNewswire
The AAV vector manufacturing market is projected to grow from USD 874 million in 2025 to USD 5.2 billion by 2034, driven by expanding gene therapy research, increasing regulatory approvals, and rising investments in biomanufacturing infrastructure. North America leads the market with 43% share, while Asia-Pacific emerges as a key growth engine. Key drivers include growing prevalence of genetic disorders, technological advancements in manufacturing, and expansion of outsourcing to CDMOs.
04/28/2026, 1:00 PM • GlobeNewswire
The drug development services market is projected to grow from $28.09 billion in 2025 to $50.26 billion by 2030 at a CAGR of 12.4%, driven by increased R&D investments, AI adoption, personalized medicine, and emerging market expansion. Key growth areas include preclinical research, regulatory optimization, and cloud-based data management, with precision medicine and genomics advancements playing pivotal roles.
04/14/2026, 10:59 AM • GlobeNewswire
ResearchAndMarkets.com is offering a two-day online training course (May 13-14, 2026) on implementing VICH Good Clinical Practice principles in veterinary clinical trials. The course aims to enhance trial efficiency, ensure regulatory compliance, and improve data quality for EU and USA acceptance. It covers protocol design, data management, monitoring, and quality assurance with expert instructors including Donna Taylor and Jenny Webster.
04/14/2026, 4:58 AM • GlobeNewswire
The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.
03/10/2026, 2:00 PM • GlobeNewswire
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans
Charles River Laboratories announced significant divestiture plans, selling its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA Holdings. The divestitures will reduce 2026 revenue by over $200 million but are expected to improve adjusted operating margins by at least 100 basis points and add approximately 10 cents to adjusted EPS. The company raised its fiscal 2026 adjusted earnings guidance to $10.80-$11.30.
02/25/2026, 9:06 AM • Benzinga
The global Adeno Associated Virus (AAV) vector manufacturing market is projected to grow from USD 2.84 billion in 2025 to USD 9.87 billion by 2035, at a CAGR of 13.4%. Growth is driven by increased clinical trials, regulatory approvals of AAV-based gene therapies, technological innovations in manufacturing processes, and rising demand from pharmaceutical companies and CDMOs. North America leads the market while Asia Pacific shows the fastest growth rate.
02/03/2026, 1:00 PM • GlobeNewswire
The global lead optimization services in drug discovery market is projected to grow from USD 4.26 billion in 2024 to USD 10.26 billion by 2034, driven by rising R&D activities, technological advancements, and increasing outsourcing trends in pharmaceutical research.
11/28/2025, 10:00 AM • GlobeNewswire
Innovative Drug CRO Market to Soar USD 96.06 Billion by 2035, Expanding at 5.44% CAGR
The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.
11/28/2025, 9:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/11/2026
Company Profile
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and de